{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:14:47Z","timestamp":1790187287243,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T00:00:00Z","timestamp":1350432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10549-012-2285-0","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T16:42:28Z","timestamp":1350492148000},"page":"759-767","source":"Crossref","is-referenced-by-count":22,"title":["Phase II open-label study of sunitinib in patients with advanced breast cancer"],"prefix":"10.1007","volume":"136","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Claire","family":"Dees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla J.","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Citrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"issue":"2","key":"2285_CR1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ije\/dyh414","volume":"34","author":"MD Althuis","year":"2005","unstructured":"Althuis MD, Dozier JD, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973\u20131997. Int J Epidemiol 34(2):405\u2013412. doi: 10.1093\/ije\/dyh414","journal-title":"Int J Epidemiol"},{"issue":"9","key":"2285_CR2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncponc0905","volume":"4","author":"S Banerjee","year":"2007","unstructured":"Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4(9):536\u2013550. doi: 10.1038\/ncponc0905","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"2285_CR3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2353\/ajpath.2009.081030","volume":"175","author":"J Paulsson","year":"2009","unstructured":"Paulsson J, Sj\u00f6blom T, Micke P, Pont\u00e9n F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstr\u00f6m K, Ostman A (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175(1):334\u2013341. doi: 10.2353\/ajpath.2009.081030","journal-title":"Am J Pathol"},{"issue":"1","key":"2285_CR4","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9(1):327\u2013337","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2285_CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4161\/cbt.2.5.446","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471\u2013478","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2285_CR6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","volume":"20","author":"LJ Murray","year":"2003","unstructured":"Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O\u2019Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20(8):757\u2013766. doi: 10.1023\/B:CLIN.0000006873.65590.68","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"2285_CR7","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr2903","volume":"13","author":"Y Kodera","year":"2011","unstructured":"Kodera Y, Katanasaka Y, Kitamura Y, Hitoshi T, Nishio K, Tamura T, Koizumi F (2011) Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13(3):R66. doi: 10.1186\/bcr2903","journal-title":"Breast Cancer Res"},{"issue":"11","key":"2285_CR8","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11):1810\u20131816. doi: 10.1200\/JCO.2007.14.5375","journal-title":"J Clin Oncol"},{"issue":"25","key":"2285_CR9","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27(25):4068\u20134075. doi: 10.1200\/JCO.2008.20.5476","journal-title":"J Clin Oncol"},{"issue":"5","key":"2285_CR10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cncr.26440","volume":"118","author":"CH Barrios","year":"2012","unstructured":"Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118(5):1252\u20131259. doi: 10.1002\/cncr.26440","journal-title":"Cancer"},{"issue":"11","key":"2285_CR11","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45(11):1959\u20131968. doi: 10.1016\/j.ejca.2009.02.011","journal-title":"Eur J Cancer"},{"issue":"3","key":"2285_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to valuate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216. doi: 10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2285_CR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144","journal-title":"J Clin Oncol"},{"issue":"5","key":"2285_CR14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1245\/ASO.2003.03.054","volume":"10","author":"GW Carlson","year":"2003","unstructured":"Carlson GW, Styblo TM, Lyles RH, Bostwick J, Murray DR, Staley CA, Wood WC (2003) Local recurrence after skin-sparing mastectomy: tumor biology or surgical conservatism? Ann Surg Oncol 10(5):575\u2013581. doi: 10.1245\/ASO.2003.03.053","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"2285_CR15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1200\/JCO.2009.27.1080","volume":"28","author":"BG Haffty","year":"2010","unstructured":"Haffty BG, Buchholz TA (2010) Molecular predictors of locoregional recurrence in breast cancer: Ready for prime time? J Clin Oncol 28(10):1627\u20131629. doi: 10.1200\/JCO.2009.27.1080","journal-title":"J Clin Oncol"},{"issue":"20","key":"2285_CR16","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(20):3271\u20133277. doi: 10.1200\/JCO.2009.24.9284","journal-title":"J Clin Oncol"},{"issue":"10","key":"2285_CR17","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","volume":"28","author":"EP Mamounas","year":"2010","unstructured":"Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677\u20131683. doi: 10.1200\/JCO.2009.23.7610","journal-title":"J Clin Oncol"},{"issue":"29","key":"2285_CR18","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2011.36.1105","volume":"29","author":"ND Arvold","year":"2011","unstructured":"Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885\u20133891. doi: 10.1200\/JCO.2011.36.1105","journal-title":"J Clin Oncol"},{"key":"2285_CR19","doi-asserted-by":"crossref","unstructured":"Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A (2010) A randomized phase II study of sunitinib vs standard of care for patients with previously treated advanced triple-negative breast cancer. Presented at the 33rd San Antonio Breast Cancer Symposium, 8\u201312 December, 2010 (poster presentation; abstract P6-12-02)","DOI":"10.1158\/0008-5472.SABCS10-P6-12-02"},{"issue":"1","key":"2285_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","volume":"121","author":"CH Barrios","year":"2010","unstructured":"Barrios CH, Liu M-C, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1):121\u2013131. doi: 10.1158\/0008-5472","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 16","key":"2285_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(Suppl 16):117\u2013124. doi: 10.1053\/j.seminoncol.2003.08.013","journal-title":"Semin Oncol"},{"issue":"1","key":"2285_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2007.15.5242","volume":"27","author":"A Moreno-Aspitia","year":"2009","unstructured":"Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 27(1):11\u201315. doi: 10.1200\/JCO.2007.15.5242","journal-title":"J Clin Oncol"},{"issue":"7","key":"2285_CR23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/CAD.0b013e32832b2ea0","volume":"20","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Pe\u00f1a C, Lathia C, Bergamini L, Gianni L (2009) Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 20(7):616\u2013624. doi: 10.1097\/CAD.0b013e32832b2ea0","journal-title":"Anticancer Drugs"},{"issue":"2","key":"2285_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","volume":"11","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11(2):82\u201392. doi: 10.1016\/j.clbc.2011.03.005","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"2285_CR25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30(9):921\u2013929. doi: 10.1200\/JCO.2011.35.7376","journal-title":"J Clin Oncol"},{"key":"2285_CR26","doi-asserted-by":"crossref","unstructured":"Crown J, Dieras V, Staroslawska E, Yardley DA, Davidson N, Bachelot TD, Tassell VR, Huang X, Kern KA, Romieu G (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer. J Clin Oncol 28(Suppl 18):Abstract LBA1011","DOI":"10.1200\/jco.2010.28.18_suppl.lba1011"},{"issue":"26","key":"2285_CR27","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666\u20132676. doi: 10.1056\/NEJMoa072113","journal-title":"N Engl J Med"},{"issue":"10","key":"2285_CR28","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Di\u00e9ras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan S, Zhou X, Phan S-C, O\u2019Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252\u20131260. doi: 10.1200\/JCO.2010.28.0982","journal-title":"J Clin Oncol"},{"issue":"20","key":"2285_CR29","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cort\u00e9s J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239\u20133247. doi: 10.1200\/JCO.2008.21.6457","journal-title":"J Clin Oncol"},{"issue":"4","key":"2285_CR30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Homes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792\u2013799. doi: 10.1200\/JCO.2005.05.098","journal-title":"J Clin Oncol"},{"key":"2285_CR31","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, Cortes J, Zhou X, Phan S, Miller K (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28(Suppl 15):Abstract 1005","DOI":"10.1200\/jco.2010.28.15_suppl.1005"},{"issue":"1","key":"2285_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0727-0","volume":"122","author":"A Valachis","year":"2010","unstructured":"Valachis A, Polyzos NP, Patsopoulous NA, Georgoulias V, Mavroudis D, Mauri D (2010) Bevacizumab in metastatic breast cancer: a meta-analysis of randomised controlled trials. Breast Cancer Res Treat 122(1):1\u20137. doi: 10.1007\/s10549-009-0727-0","journal-title":"Breast Cancer Res Treat"},{"key":"2285_CR33","doi-asserted-by":"crossref","unstructured":"Gradishar WJ, Kaklamani V, Prasad TS, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M (2009) A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer. Cancer Res 69(24 Suppl 3):Abstract 44. doi: 10.1158\/0008-5472.SABCS-09-44","DOI":"10.1158\/0008-5472.SABCS-09-44"},{"key":"2285_CR34","doi-asserted-by":"crossref","unstructured":"Baselga J, Grupo Espa\u00f1ol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores S\u00f3lidos, Roch\u00e9 H, Costa F, Get\u00falio Martins Segalla J, Pinczowski H, Ma Ciruelos E, Cabral Filho, S, G\u00f3mez P, Van Eyll B (2009) SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafinib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 69(Suppl 24):Abstract 45. doi: 10.1158\/0008-5472.SABCS-09-45","DOI":"10.1158\/0008-5472.SABCS-09-45"},{"issue":"2","key":"2285_CR35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1359-6349(09)70921-8","volume":"7","author":"P Kaufman","year":"2009","unstructured":"Kaufman P, de Boer R, White S, Mainwaring P, Koczwara B, Urquhart LM, Ye Y, Sun Y, Adewoye H, Kotasek D (2009) Motesanib (AMG 706) in combination with paclitaxel or docetaxel: phase 1b study in patients with locally recurrent, unresectable or metastatic breast cancer. Eur J Cancer Suppl 7(2):269","journal-title":"Eur J Cancer Suppl"},{"key":"2285_CR36","doi-asserted-by":"crossref","unstructured":"Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagie\u0142\u0142o-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Ba\u00f1os A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR, TRIO 010 investigators (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12(4):369\u2013376. doi: 10.1016\/S1470-2045(11)70037-7","DOI":"10.1016\/S1470-2045(11)70037-7"},{"issue":"18","key":"2285_CR37","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","volume":"29","author":"HS Rugo","year":"2011","unstructured":"Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D (2011) Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 29(18):2459\u20132465. doi: 10.1200\/JCO.2010.31.2975","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2285-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2285-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T19:17:19Z","timestamp":1562267839000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2285-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,17]]}}}